Baseline characteristics and outcomes in patients with first episode or multiple episodes of acute mania

Journal of Clinical Psychiatry

Volumn 71, Issue 3, 2010, Pages 255-261

  Tohen, Mauricio ^a,b,c   Vieta, Eduard ^c,d   Gonzalez Pinto, Ana ^e   Reed, Catherine ^b   Lin, Daniel ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c MCLEAN HOSPITAL   (United States)

^d UNIVERSITY OF BARCELONA   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; HYPNOTIC AGENT; LITHIUM CARBONATE; NEUROLEPTIC AGENT; OLANZAPINE; TRANQUILIZER;

ADULT; ARTICLE; BIPOLAR MANIA; BODY MASS; CANNABIS ADDICTION; CLINICAL GLOBAL IMPRESSION SCALE; CONVALESCENCE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMAN; MAJOR CLINICAL STUDY; MANIA; MONOTHERAPY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; SUICIDE ATTEMPT; YOUNG MANIA RATING SCALE;

ADULT; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; SUBSTANCE-RELATED DISORDERS; SUICIDE, ATTEMPTED; TREATMENT OUTCOME;

EID: 77950331526     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04580     Document Type: Article

References (31)

1. Tohen M, Waternaux CM, Tsuang MT. Outcome in mania: a 4-year prospective follow-up of 75 patients utilizing survival analysis. Arch Gen Psychiatry. 1990;47(12):1106-1111.
2. Keck PE Jr, McElroy SL, Strakowski SM, et al. Outcome and comorbidity in first- compared with multiple-episode mania. J Nerv Ment Dis. 1995;183(5):320-324.
3. Tohen M, Waternaux CM, Tsuang MT, et al. Four-year follow-up of twenty-four first-episode manic patients. J Affect Disord. 1990;19(2):79-86.
4. Tohen M, Zarate CA, Zarate SB, et al. The McLean/Harvard first-episode study: pharmacological treatment & outcome. Psychiatr Ann. 1996:S444-S448.
5. Tohen M, Strakowski SM, Zarate C Jr, et al. The McLean-Harvard first-episode project: 6-month symptomatic and functional outcome in affective and nonaffective psychosis. Biol Psychiatry. 2000;48(6):467-476.
6. Goetz I, Tohen M, Reed C, et al. Functional impairment in patients with mania: baseline results of the EMBLEM study. Bipolar Disord. 2007;9(1-2):45-52.
7. Haro JM, van Os J, Vieta E, et al. Evidence for three distinct classes of 'typical,' 'psychotic' and 'dual' mania: results from the EMBLEM study. Acta Psychiatr Scand. 2006;113(2):112-120.
8. Vieta E, Panicali F, Goetz I, et al. Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational study. J Affect Disord 2008; 106(1-2):63-72.
9. Van Riel WG, Vieta E, Martinez-Aran A, et al. Chronic mania revisited: factors associated with treatment non-response during prospective follow-up of a large European cohort (EMBLEM). World J Biol Psychiatry. 2008;9(4):313-320.
10. Spearing MK, Post RM, Leverich GS, et al. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGIBP. Psychiatry Res. 1997;73(3):159-171.
11. Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429-435.
12. Gonzalez-Pinto A, Ballesteros J, Aldama A, et al. Principal components of mania. J Affect Disord. 2003;76(1):95-102.
13. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002;159(6):1011-1017.
14. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003;60(12):1218-1226.
15. Keller MB, Lavori PW, Friedman B, et al. The Longitudinal Interval Follow-up Evaluation: a comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry. 1987;44(6): 540-548.
16. MacQueen GM, Young LT, Robb JC, et al. Effect of number of episodes on wellbeing and functioning of patients with bipolar disorder. Acta Psychiatr Scand. 2000;101(5):374-381.
17. Robinson LJ, Ferrier IN. Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. Bipolar Disord. 2006;8(2):103-116.
18. Tohen M, Zarate CA Jr, Hennen J, et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry. 2003;160(12):2099-2107.
19. Berk M, Hallam KT, McGorry PD. The potential utility of a staging model as a course specifier: a bipolar disorder perspective. J Affect Disord. 2007;100(1-3):279-281.
20. Baethge C, Baldessarini RJ, Khalsa HM, et al. Substance abuse in first-episode bipolar I disorder: indications for early intervention. Am J Psychiatry. 2005;162(5):1008-1010.
21. Cassidy F, Ahearn EP, Carroll BJ. Substance abuse in bipolar disorder. Bipolar Disord. 2001;3(4):181-188.
22. Strakowski SM, DelBello MP, Fleck DE, et al. The impact of substance abuse on the course of bipolar disorder. Biol Psychiatry. 2000;48(6): 477-485.
23. Perlis RH, Ostacher MJ, Patel JK, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry. 2006;163(2):217-224.
24. Strakowski SM, Keck PE Jr, McElroy SL, et al. Twelve-month outcome after a first hospitalization for affective psychosis. Arch Gen Psychiatry. 1998;55(1):49-55.
25. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59(6):530-537.
26. Gonzalez-Pinto A, Mosquera F, Alonso M, et al. Suicidal risk in bipolar I disorder patients and adherence to long-term lithium treatment. Bipolar Disord. 2006;8(5 Pt2):618-624.
27. Lopez P, Mosquera F, de Leon J, et al. Suicide attempts in bipolar patients. J Clin Psychiatry. 2001;62(12):963-966.
28. Goldberg JF, Garno JL, Harrow M. Long-term remission and recovery in bipolar disorder: a review. Curr Psychiatry Rep. 2005;7(6):456-461.
29. Kapczinski F, Vieta E, Andreazza AC, et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev. 2008;32(4):675-692.
30. Post RM. Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neurosci Biobehav Rev. 2007;31(6)858-873.
31. Tohen M, Bowden CL, Calabrese JR, et al. Influence of sub-syndromal symptoms after remission from manic or mixed episodes. Br J Psychiatry. 2006;189:515-519